Our Commitment
BiopharmaWatch is built on accuracy, independence, and timeliness. Our users depend on this data when making investment decisions, and we take that responsibility seriously. We have no affiliation with any pharmaceutical company, broker-dealer, or investment fund.
Data Sources
Everything we publish comes from primary, authoritative sources. We never rely on third-party aggregators as our main data providers.
- FDA Regulatory Data: Pulled directly from FDA.gov, including PDUFA dates, advisory committee schedules, approval letters, and Complete Response Letters (CRLs).
- Clinical Trial Data: Sourced from ClinicalTrials.gov, the U.S. National Library of Medicine's registry of clinical studies.
- SEC Filings: Insider trading data (Form 4) and institutional holdings (13F) come directly from SEC EDGAR.
- Company Filings: Press releases, 8-K filings, and earnings reports are pulled from SEC EDGAR and official company investor relations pages.
Update Frequency
FDA CalendarUpdated daily
PDUFA DatesUpdated within 24 hours of FDA action
Insider Trading (Form 4)Processed within hours of filing
Hedge Fund Holdings (13F)Updated quarterly after SEC deadline
Company ScreenerRefreshed daily with market data
Blog & AnalysisReviewed and refreshed when underlying data changes
Probability of Approval (POA) Methodology
Our POA scores are based on a combination of:
- Historical FDA approval rates by therapeutic area and indication
- Clinical trial endpoint data (efficacy and safety outcomes)
- Regulatory designation status (Breakthrough Therapy, Fast Track, Priority Review, Accelerated Approval)
- Advisory committee voting outcomes, when applicable
- Complete Response Letter history and resubmission data
Every POA score comes with a written summary that explains the reasoning. We update scores when new material data comes in, like fresh trial results, an advisory committee vote, or new FDA communications.
Fact-Checking Process
Before anything gets published, it goes through this review process:
- Source Verification: Every claim is traced back to a primary source (FDA, SEC, ClinicalTrials.gov, or an official company filing).
- Data Cross-Reference: Key data points are checked against at least one additional source when available.
- Editorial Review: Content is reviewed by team members with biotech domain expertise before it goes live.
- Citation Requirement: We cite primary sources in every article. If a claim can't be sourced, it doesn't get published.
Use of AI
We use AI tools to help with data processing, research, and content drafting. That said, every piece of AI-assisted content is reviewed and edited by a human with biotech expertise before it gets published. AI is a tool we use under human supervision, not a replacement for it.
Correction Policy
When we find an error in something we've published:
- We fix it within 24 hours.
- Material corrections get an inline note with the date of the fix.
- If a correction changes the substance of an analysis, we publish an update explaining what changed and why.
- We don't quietly edit published content without noting the change.
Found something that looks wrong? Please let us know and we'll look into it right away.
Independence and Conflicts of Interest
BiopharmaWatch is fully independent. We're not sponsored by, affiliated with, or under the editorial control of any pharmaceutical company, broker-dealer, investment fund, or financial institution. Our coverage is driven by the data and its relevance to investors, not by advertising or business relationships.
Contact
Have questions about how we do things? Feel free to reach out. We're always open to feedback and looking for ways to improve.